Novel Clinical Stage Treatments for Epilepsy and Pain
Summary The principal investigator has discovered that Huperzine A (HupA) is characterized by extremely potent therapeutic activity against epilepsy and chronic pain. HupA was tested in a formalin model of pain, in which it produced complete inhibition of pain behavior in all treated mice, with a dosage well below known TD50 values. HupA has also shown extensive evidence for being effective in various animal models of epilepsy, including the 6-Hz mouse model.
Clinical studies are being pursued in 2007.
Applications The markets being pursued are epilepsy, where despite a number of effective drugs on the market there remains a large unmet medical need, and pain (both chronic and acute), another large market need. For Further Information Please Contact the Director of Business Development Katie Gordon Email: email@example.com Telephone: (617) 432-0920
Schachter, Steven C.
Type of Offer:
« More Chemistry Patents« More Medical Patents